| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGLE | Exit | Aeglea BioTherapeutics | $0 | – | -6,000 | -100.0% | -0.03% | – |
| DNAI | Exit | ProNAI Therapeutics Inc | $0 | – | -56,056 | -100.0% | -0.09% | – |
| BOLD | Exit | Audentes Therapeutics | $0 | – | -15,000 | -100.0% | -0.30% | – |
| CTMX | Exit | CytomX Therapeutics Inc | $0 | – | -64,200 | -100.0% | -0.76% | – |
| AKTX | Exit | Akari Therapeutics Plc | $0 | – | -158,352 | -100.0% | -1.20% | – |
| ABIO | Exit | ARCA biopharma Inc | $0 | – | -462,399 | -100.0% | -1.42% | – |
| ADHD | Exit | Alcobra Ltd | $0 | – | -658,910 | -100.0% | -1.49% | – |
| STML | Exit | Stemline Therapeutics Inc | $0 | – | -135,420 | -100.0% | -1.56% | – |
| EDGE | Exit | Edge Therapeutics Inc | $0 | – | -135,000 | -100.0% | -1.82% | – |
| ASND | Exit | Ascendis Pharma A/S | $0 | – | -90,000 | -100.0% | -1.96% | – |
| OCRX | Exit | Ocera Therapeutics | $0 | – | -912,050 | -100.0% | -2.06% | – |
| AXGT | Exit | Axovant Sciences Ltd | $0 | – | -184,110 | -100.0% | -2.46% | – |
| CLCD | Exit | CoLucid Pharmaceuticals | $0 | – | -68,190 | -100.0% | -2.67% | – |
| LPCN | Exit | Lipocine Inc | $0 | – | -849,921 | -100.0% | -3.36% | – |
| ADVM | Exit | Adverum Biotechnologies | $0 | – | -1,102,735 | -100.0% | -3.44% | – |
| RARX | Exit | Ra Pharmaceuticals | $0 | – | -232,500 | -100.0% | -3.80% | – |
| FLML | Exit | Avadel Pharmaceuticals | $0 | – | -500,000 | -100.0% | -5.59% | – |
| BCRX | Exit | BioCryst Pharmaceuticals Inc | $0 | – | -1,155,104 | -100.0% | -7.86% | – |
| CHRS | Exit | Coherus Biosciences Inc | $0 | – | -305,505 | -100.0% | -9.25% | – |
| HRTX | Exit | Heron Therapeutics Inc | $0 | – | -1,095,734 | -100.0% | -15.44% | – |
| Exit | DBV Technologies | $0 | – | -456,893 | -100.0% | -33.47% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.